REGINfo: Biogen Idec Inc - Biotechnologie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

S&P 100 NEWS

> 21st Century Fox Inc

> Accenture PLC

> Allstate Corp.

> Altria Group, Inc.

> Amazon.com Inc

> American Express

> American International Group

> Bank of America

> Bank of New York Mellon Corp

> Berkshire Hathaway Inc.

> Biogen Idec Inc

> Booking Holdings

> Bristol-Myers Squibb Co.

> Caterpillar Inc.

> Charter Communication

> Cisco Systems Inc

> Coca Cola Co.

> Colgate-Palmolive

> ConocoPhillips

> Costco Wholesale Corp

> CVS Caremark Corp.

> Eli Lilly & Co.

> Emerson Electric Co.

> Exelon Corporation

> Exxon Mobil Corp.

> Ford Motor Company

> General Dynamics

> General Electric

> General Motors

> Gilead Sciences Inc

> Goldman Sachs Group, Inc.

> Halliburton Co.

> Home Depot, Inc

> Honeywell International, Inc.

> International Business Machines (IBM)

> Johnson & Johnson

> JP Morgan Chase & Co

> Kinder Morgan Inc

> Lockheed Martin

> Lowes Companies

> Mastercard Inc A

> McDonald's Corp.

> Medtronic, Inc.

> Merck & Co., Inc.

> Mondelez International Inc

> Morgan Stanley

> NextEra Energy Inc

> ...

FEEDS

My Google

Microsoft Live

My Yahoo

COMPANY SEARCH RESULT

$Biogen Idec Inc: Click to view the issuer\'s details$

Last update : 21/08/2018 >View issuer details

2019.10.02 | 13:30 | Permanent Information Releases / General Company News

puce Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders - HTML (w)

2019.10.01 | 14:00 | Permanent Information Releases / General Company News

puce Biogen Announces Leadership Update - HTML (w)

2019.09.23 | 09:00 | Permanent Information Releases / General Company News

puce Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding - HTML (w)

2019.09.18 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients - HTML (w)

2019.09.17 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index - HTML (w)

2019.09.12 | 11:00 | Permanent Information Releases / General Company News

puce New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum - HTML (w)

2019.09.11 | 11:00 | Permanent Information Releases / General Company News

puce New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years - HTML (w)

2019.07.30 | 13:30 | Permanent Information Releases / General Company News

puce Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis - HTML (w)

2019.07.01 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients - HTML (w)

2019.06.29 | 10:00 | Permanent Information Releases / General Company News

puce Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy - HTML (w)

2019.06.12 | 01:05 | Permanent Information Releases / General Company News

puce Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019 - HTML (w)

2019.06.07 | 11:41 | Permanent Information Releases / General Company News

puce Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million - HTML (w)

2019.05.30 | 13:30 | Permanent Information Releases / General Company News

puce New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis - HTML (w)

2019.05.20 | 13:30 | Permanent Information Releases / General Company News

puce Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation - HTML (w)

2019.05.15 | 01:02 | Permanent Information Releases / General Company News

puce Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 / Doc nb : 72